Treatment News : FDA Approves Generic Reyataz for Use Abroad Via PEPFAR

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 5, 2014

FDA Approves Generic Reyataz for Use Abroad Via PEPFAR

The U.S. Food and Drug Administration has granted “tentative approval” to a generic formulation of Reyataz (atazanavir) to treat HIV abroad. The approval is for 100 milligram, 150 mg, 200 mg and 300 mg atazanavir capsules for use in combination with other antiretrovirals to treat HIV. The generic version of the Bristol-Myers Squibb medication is manufactured by Aurobindo Pharma in Hyderabad, India.

By granting only tentative approval, the FDA indicates that atazanavir has satisfied all quality, safety and efficacy standards but does not qualify for use in the United States because of existing patent protections on Reyataz. Instead, the drug will be available for purchase internationally through the President’s Emergency Plan for AIDS Relief (PEPFAR) program, which provides HIV care, prevention and treatment, among other services, to many hard-hit nations abroad.

To read the press release, click here.

Search: Food and Drug Administration, FDA, tentative approval, HIV, Reyataz, PEPFAR, atazanavir, generic, President's Emergency Plan for AIDS Relief, Aurobindo Pharma, Bristol-Myers Squibb, BMS

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.